JP2011500776A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500776A5 JP2011500776A5 JP2010530555A JP2010530555A JP2011500776A5 JP 2011500776 A5 JP2011500776 A5 JP 2011500776A5 JP 2010530555 A JP2010530555 A JP 2010530555A JP 2010530555 A JP2010530555 A JP 2010530555A JP 2011500776 A5 JP2011500776 A5 JP 2011500776A5
- Authority
- JP
- Japan
- Prior art keywords
- mbp
- composition according
- composition
- treating
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000047918 Myelin Basic Human genes 0.000 claims description 7
- 101710107068 Myelin basic protein Proteins 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 208000003435 Optic Neuritis Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108010051539 HLA-DR2 Antigen Proteins 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 description 6
- 108010080451 HLA-DQ6 antigen Proteins 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0721430.7 | 2007-10-31 | ||
| GB0721430A GB0721430D0 (en) | 2007-10-31 | 2007-10-31 | Composition |
| GB0800962A GB0800962D0 (en) | 2008-01-18 | 2008-01-18 | Conposition |
| GB0800962.3 | 2008-01-18 | ||
| PCT/GB2008/003673 WO2009056833A2 (en) | 2007-10-31 | 2008-10-30 | Composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500776A JP2011500776A (ja) | 2011-01-06 |
| JP2011500776A5 true JP2011500776A5 (enExample) | 2011-10-06 |
| JP5361895B2 JP5361895B2 (ja) | 2013-12-04 |
Family
ID=40591554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530555A Active JP5361895B2 (ja) | 2007-10-31 | 2008-10-30 | 組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US8623827B2 (enExample) |
| EP (1) | EP2211892B1 (enExample) |
| JP (1) | JP5361895B2 (enExample) |
| KR (1) | KR101570383B1 (enExample) |
| CN (1) | CN101848725B (enExample) |
| AT (1) | ATE518546T1 (enExample) |
| AU (1) | AU2008320657B2 (enExample) |
| BR (1) | BRPI0818302B1 (enExample) |
| CA (1) | CA2703170C (enExample) |
| CY (1) | CY1112620T1 (enExample) |
| DK (1) | DK2211892T3 (enExample) |
| EA (1) | EA017999B1 (enExample) |
| EC (1) | ECSP10010211A (enExample) |
| HR (1) | HRP20110724T1 (enExample) |
| IL (1) | IL204662A (enExample) |
| MX (1) | MX2010004698A (enExample) |
| MY (1) | MY158800A (enExample) |
| NZ (1) | NZ583924A (enExample) |
| PL (1) | PL2211892T3 (enExample) |
| PT (1) | PT2211892E (enExample) |
| SI (1) | SI2211892T1 (enExample) |
| WO (1) | WO2009056833A2 (enExample) |
| ZA (1) | ZA201001748B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1311542T1 (sl) | 2000-08-21 | 2009-02-28 | Apitope Technology Bristol Ltd | Tolerogenski peptidi |
| US8623827B2 (en) | 2007-10-31 | 2014-01-07 | Apitope Technology (Bristol) Limited | Myelin basic protein peptide composition |
| WO2011046462A1 (en) * | 2009-10-12 | 2011-04-21 | Angport Limited | Composition for treatment of multiple sclerosis |
| GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
| GB201603582D0 (en) * | 2016-03-01 | 2016-04-13 | Apitope Int Nv | Peptides |
| ES2996275T3 (en) * | 2017-01-04 | 2025-02-12 | Worg Pharmaceuticals Zhejiang Co Ltd | Therapeutic method using dose escalation protocol for tolerogenic peptides |
| GB201700095D0 (en) * | 2017-01-04 | 2017-02-22 | Apitope Int Nv | Composition |
| US20210093695A1 (en) * | 2017-08-14 | 2021-04-01 | Apitope Technology (Bristol) Limited | Method |
| JP2024518277A (ja) | 2021-04-16 | 2024-05-01 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | 免疫寛容の維持を追跡する方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817629A (en) | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| SI1311542T1 (sl) * | 2000-08-21 | 2009-02-28 | Apitope Technology Bristol Ltd | Tolerogenski peptidi |
| US20040096456A1 (en) | 2000-12-01 | 2004-05-20 | Conti-Fine Bianca M | Method to treat hemophilia |
| GB0202399D0 (en) * | 2002-02-01 | 2002-03-20 | Univ Bristol | Peptide |
| US8623827B2 (en) | 2007-10-31 | 2014-01-07 | Apitope Technology (Bristol) Limited | Myelin basic protein peptide composition |
-
2008
- 2008-10-30 US US12/740,976 patent/US8623827B2/en active Active
- 2008-10-30 BR BRPI0818302-3A patent/BRPI0818302B1/pt active IP Right Grant
- 2008-10-30 DK DK08844568.9T patent/DK2211892T3/da active
- 2008-10-30 EA EA201070541A patent/EA017999B1/ru not_active IP Right Cessation
- 2008-10-30 EP EP08844568A patent/EP2211892B1/en active Active
- 2008-10-30 AU AU2008320657A patent/AU2008320657B2/en active Active
- 2008-10-30 CN CN2008801138365A patent/CN101848725B/zh active Active
- 2008-10-30 SI SI200830411T patent/SI2211892T1/sl unknown
- 2008-10-30 NZ NZ583924A patent/NZ583924A/en unknown
- 2008-10-30 WO PCT/GB2008/003673 patent/WO2009056833A2/en not_active Ceased
- 2008-10-30 CA CA2703170A patent/CA2703170C/en active Active
- 2008-10-30 PT PT08844568T patent/PT2211892E/pt unknown
- 2008-10-30 JP JP2010530555A patent/JP5361895B2/ja active Active
- 2008-10-30 HR HR20110724T patent/HRP20110724T1/hr unknown
- 2008-10-30 MY MYPI2010001917A patent/MY158800A/en unknown
- 2008-10-30 AT AT08844568T patent/ATE518546T1/de active
- 2008-10-30 KR KR1020107005853A patent/KR101570383B1/ko active Active
- 2008-10-30 MX MX2010004698A patent/MX2010004698A/es active IP Right Grant
- 2008-10-30 PL PL08844568T patent/PL2211892T3/pl unknown
-
2010
- 2010-03-11 ZA ZA2010/01748A patent/ZA201001748B/en unknown
- 2010-03-22 IL IL204662A patent/IL204662A/en active IP Right Grant
- 2010-05-28 EC EC2010010211A patent/ECSP10010211A/es unknown
-
2011
- 2011-10-25 CY CY20111101006T patent/CY1112620T1/el unknown
-
2013
- 2013-12-06 US US14/099,463 patent/US9381234B2/en active Active
-
2016
- 2016-06-03 US US15/173,018 patent/US9775880B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500776A5 (enExample) | ||
| UA94734C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ | |
| JP2019517542A5 (enExample) | ||
| JP2016074740A5 (enExample) | ||
| CA2923685A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| JP2016518387A5 (enExample) | ||
| JP2013520405A5 (enExample) | ||
| WO2015024667A8 (en) | Method for increasing expression of rna-encoded proteins | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| JP2012505883A5 (enExample) | ||
| JP2015518818A5 (enExample) | ||
| BR112014027010A2 (pt) | uso de laquinimod de alta dose para tratamento de esclerose múltipla | |
| JP2017506624A5 (enExample) | ||
| JP2010532761A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
| JP2013518124A5 (enExample) | ||
| JP2013541583A5 (enExample) | ||
| JP2017503014A5 (enExample) | ||
| CY1112620T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν πεπτιδια βασικης πρωτεϊνης της μυελινης και ιατρικες χρησεις αυτων | |
| JP2020533302A5 (enExample) | ||
| CN103102393B (zh) | 一种多肽及其在制备抑郁症治疗药物中的应用 | |
| JP2018521007A5 (enExample) | ||
| JP2020502056A5 (enExample) | ||
| Wasan et al. | Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients |